Abstract
Mutations in the epigenetic modifiers DNMT3A and TET2 non-randomly co-occur in lymphoma and leukemia despite their epistasis in the methylation–hydroxymethylation pathway. Using Dnmt3a and Tet2 double-knockout mice in which the development of malignancy is accelerated, we show that the double-knockout methylome reflects regions of independent, competitive and cooperative activity. Expression of lineage-specific transcription factors, including the erythroid regulators Klf1 and Epor, is upregulated in double-knockout hematopoietic stem cells (HSCs). DNMT3A and TET2 both repress Klf1, suggesting a model of cooperative inhibition by epigenetic modifiers. These data demonstrate a dual role for TET2 in promoting and inhibiting HSC differentiation, the loss of which, along with DNMT3A, obstructs differentiation, leading to transformation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009).
Inoue, A. & Zhang, Y. Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science 334, 194 (2011).
Ley, T.J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2433 (2010).
Walter, M.J. et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25, 1153–1158 (2011).
Grossmann, V. et al. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosom. Cancer 52, 410–422 (2013).
Van Vlierberghe, P. et al. ETV6 mutations in early immature human T cell leukemias. J. Exp. Med. 208, 2571–2579 (2011).
Pastor, W.A. et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473, 394–397 (2011).
Abdel-Wahab, O. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114, 144–147 (2009).
Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009).
Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478 (2014).
Welch, J.S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).
Shlush, L.I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014).
Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C. & Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl. Acad. Sci. USA 111, 2548–2553 (2014).
Challen, G.A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44, 23–31 (2012).
Mayle, A. et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood 125, 629–638 (2015).
Celik, H. et al. Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood 125, 619–628 (2015).
Ko, M. et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl. Acad. Sci. USA 108, 14566–14571 (2011).
Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11–24 (2011).
Li, Z. et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118, 4509–4518 (2011).
Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25–38 (2011).
Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839–843 (2010).
Figueroa, M.E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).
Madzo, J. et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep. 6, 231–244 (2014).
Russler-Germain, D.A. et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25, 442–454 (2014).
Palomero, T. et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet. 46, 166–170 (2014).
Couronné, L., Bastard, C. & Bernard, O.A. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 366, 95–96 (2012).
Sakata-Yanagimoto, M. et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat. Genet. 46, 171–175 (2014).
Scourzic, L. et al. DNMT3AR882H mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia 30, 1388–1398 (2016).
Chambers, S.M. et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell Stem Cell 1, 578–591 (2007).
Tallack, M.R. et al. Novel roles for KLF1 in erythropoiesis revealed by mRNA-seq. Genome Res. 22, 2385–2398 (2012).
Tallack, M.R. et al. A global role for KLF1 in erythropoiesis revealed by ChIP-seq in primary erythroid cells. Genome Res. 20, 1052–1063 (2010).
Hasemann, M.S. et al. C/EBPα is required for long-term self-renewal and lineage priming of hematopoietic stem cells and for the maintenance of epigenetic configurations in multipotent progenitors. PLoS Genet. 10, e1004079 (2014).
Schwickert, T.A. et al. Stage-specific control of early B cell development by the transcription factor Ikaros. Nat. Immunol. 15, 283–293 (2014).
Shu, J. et al. Induction of pluripotency in mouse somatic cells with lineage specifiers. Cell 153, 963–975 (2013).
Orkin, S.H. Priming the hematopoietic pump. Immunity 19, 633–634 (2003).
Lessene, G. et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 9, 390–397 (2013).
Jeong, M. et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat. Genet. 46, 17–23 (2014).
Ziller, M.J. et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 500, 477–481 (2013).
Rasmussen, K.D. et al. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev. 29, 910–922 (2015).
Lara-Astiaso, D. et al. Chromatin state dynamics during blood formation. Science 345, 943–949 (2014).
Huang, Y. et al. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One 5, e8888 (2010).
Huang, Y., Pastor, W.A., Zepeda-Martínez, J.A. & Rao, A. The anti-CMS technique for genome-wide mapping of 5-hydroxymethylcytosine. Nat. Protoc. 7, 1897–1908 (2012).
Shen, L. et al. Genome-wide analysis reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics. Cell 153, 692–706 (2013).
Williams, K. et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473, 343–348 (2011).
Wu, H. et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 473, 389–393 (2011).
Ficz, G. et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 473, 398–402 (2011).
Challen, G.A. et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell 15, 350–364 (2014).
Tsagaratou, A. et al. Dissecting the dynamic changes of 5-hydroxymethylcytosine in T-cell development and differentiation. Proc. Natl. Acad. Sci. USA 111, E3306–E3315 (2014).
Zhao, Z. et al. Combined loss of Tet1 and Tet2 promotes B cell, but not myeloid malignancies, in mice. Cell Rep. 13, 1692–1704 (2015).
An, J. et al. Acute loss of TET function results in aggressive myeloid cancer in mice. Nat. Commun. 6, 10071 (2015).
Cimmino, L. et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat. Immunol. 16, 653–662 (2015).
Wang, L. et al. Molecular basis for 5-carboxycytosine recognition by RNA polymerase II elongation complex. Nature 523, 621–625 (2015).
Guo, G. et al. Mapping cellular hierarchy by single-cell analysis of the cell surface repertoire. Cell Stem Cell 13, 492–505 (2013).
Nimmo, R.A., May, G.E. & Enver, T. Primed and ready: understanding lineage commitment through single cell analysis. Trends Cell Biol. 25, 459–467 (2015).
Mayle, A., Luo, M., Jeong, M. & Goodell, M.A. Flow cytometry analysis of murine hematopoietic stem cells. Cytometry A 83, 27–37 (2013).
Pollier, J., Rombauts, S. & Goossens, A. Analysis of RNA-Seq data with TopHat and Cufflinks for genome-wide expression analysis of jasmonate-treated plants and plant cultures. Methods Mol. Biol. 1011, 305–315 (2013).
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
Sun, D. et al. MOABS: model based analysis of bisulfite sequencing data. Genome Biol. 15, R38 (2014).
Zhang, Y. et al. QDMR: a quantitative method for identification of differentially methylated regions by entropy. Nucleic Acids Res. 39, e58 (2011).
Quinlan, A.R. BEDTools: the Swiss-army tool for genome feature analysis. Curr. Protoc. Bioinformatics 47, 11.12.1–11.12.34 (2014).
Xi, Y. & Li, W. BSMAP: whole genome bisulfite sequence MAPping program. BMC Bioinformatics 10, 232 (2009).
Chen, K. et al. DANPOS: dynamic analysis of nucleosome position and occupancy by sequencing. Genome Res. 23, 341–351 (2013).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
Huang, D.W. et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8, R183 (2007).
Acknowledgements
We thank M. Kampmann for discussions at AACR, C. Gillespie for editing, and R. Nitsal, S. Hexige and Y. Zheng for assistance with histology, pathology and BMT, respectively. X.Z. is supported by the Wellcome Trust Gene–Environment training program. This work was supported by the US NIH (DK092883, CA183252, HG007538, CA193466, CA125123, P50CA126752 and CA151535), the Samuel Waxman Medical Research Foundation, the Edward P. Evans Foundation, the Adrienne Helis Malvin Medical Research Foundation, the Leukemia and Lymphoma Society (Translational Research Program to A.R. and Special Fellow Award to M.K.), and CPRIT (RP140001) and a CPRIT Scholar award to Y.H. (RP140053).
Author information
Authors and Affiliations
Contributions
X.Z. and M.A.G. conceived and discussed the project with Y.H., M.K. and A.R. X.Z. analyzed phenotypes and performed shRNA knockdown with M.J. J.S. analyzed the WGBS and RNA-seq data with H.J.P. M.J. performed HSC sorting and WGBS and RNA-seq analyses. M.K. and A.R. provided Tet2−/− mice. Y.H. generated CMS libraries. A.G., Y.L. and Y.-H.H. performed experiments. X.Z. led the project and drafted the manuscript. All authors participated in discussions, data interpretation and manuscript editing. M.A.G. and W.L. provided funding and supervision.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Experimental procedure and replating assay in vitro.
(a) The experimental scheme depicting bone marrow transplantation from mice with all four genotypes. (b) Serial replating assay with WT, Dnmt3a−/−, Tet2–/– and DKO bone marrow cells. (c) Representative Giemsa-stained images after serial plating cells from WT and DKO bone marrow. 400× magnification. Scale bar, 20 μm. (d) RNA-seq results from the indicated genotypes. The blue shaded region indicates exons 7–9 of Tet2, absent in Tet2−/− and DKO HSCs. (e) RNA-seq result across the Dnmt3a gene from HSCs with the indicated genotypes. The pink shaded area indicates exon 17, which is deleted in the Dnmt3a transcript after Cre-mediated recombination in Dnmt3a−/− and DKO HSCs.
Supplementary Figure 2 Histology analysis of WT, Dnmt3a−/−, Tet2−/− and DKO recipient mice.
(a) Representative bone marrow hematoxylin and eosin staining of age-matched recipient mice of four genotypes. A representative DKO mouse depicts bone marrow hyperplasia (i). Scale bar, 20 μm. Representative DKO mice depict dysmegakaryopoiesis with features of emperipolesis (ii, left) and hypolobulated nuclei (ii, right). Scale bar, 20 μm. Bone marrow fibrosis is also observed in DKO mice (iii). (b) Representative spleen hematoxylin and eosin staining of age-matched recipient mice of four genotypes. Scale bar, 50 μm. (c) Representative liver hematoxylin and eosin staining of age-matched recipient mice of four genotypes. Scale bar, 50 μm. (d) Representative lung hematoxylin and eosin staining of age-matched recipient mice of four genotypes. Scale bar, 100 μm.
Supplementary Figure 3 DNMT3A and TET2 loss synergistically induces lymphoid disease.
(a) A recipient of DKO bone marrow after 7 months showing B cell infiltration of the salivary gland. A WT mouse in the cohort was used as control (left). Middle, FACS analysis of infiltrated cells. Right, histology comparing the normal gland (from a Dnmt3a−/− recipient) to a gland with infiltration (the dotted line shows the remaining epithelial gland structure). Scale bar, 50 μm. (b) A DKO mouse without transplantation developed B cell lymphoma. Right, FACS analysis with B cell and T cell markers. (c) Hematological analysis from a representative DKO-transplanted mouse that developed B-ALL 9 months after bone marrow transplantation and a Tet2−/− transplanted mouse for comparison. Top and middle scale bars, 20 μm. Bottom, FACS analysis of peripheral blood. (d,e) Analysis of representative secondary recipients of DKO cells demonstrating T cell thymic lymphoma with cell surface marker for immature cells (e) sacrificed at the same time point. The black dotted line indicates the position of the thymus.
Supplementary Figure 4 Expression of major HSC transcription factors.
(a–d) Expression (FPKM) of major HSC transcription factors (Gata2, Meis1, Runx1, Lmo2) that are not differentially expressed. (e–g) The expression (FPKM mean) of DNA methylation regulators is not significantly altered in HSCs from single and double knockouts relative to WT. (h,i) Cebpe and Ikzf1 show significantly different expression. All data are shown as mean ± s.d. *P < 0.05. **P < 0.01; ns, not significant; n =2. P values were calculated by cuffdiff in the RNA-seq analysis pipeline. (j) Correlation of the transcriptomes of HSCs of all genotypes with differentiated lineages and committed progenitors. The boxed region shows the stronger correlation between the progenitor population and Tet2−/− and DKO HSCs43. (k,l) Box plots depicting the range of expression of Cebpa (k) and Ebf1 (l) target genes from previous ChIP-seq and gene expression data35,36. All data in d–n are plotted from RNA-seq analysis with duplicates for each genotype.
Supplementary Figure 5 Patients with AML from TCGA carrying both TET2 and DNMT3A mutations show activation of KLF1 and its downstream targets.
(a) RBC gene overexpression in patients carrying both TET2 and DNMT3A mutations. (b) Venn diagrams showing the overlap of genes activated in patients and genes upregulated in DKO HSCs. The P value was calculated by two-tailed Fisher’s exact test.
Supplementary Figure 6 DNMT3A and TET2 counteract each other at canyon edges.
(a) Basic quality control statistics for the WGBS sequencing results. (b) Methylation levels of all DMRs of six major DMAPs in HSCs of all four genotypes. (c) Pie chart showing the makeup of genomic regions with dynamic DMR patterns. (d) Distribution of DMRs of DMAPs in genomic regions. (e) Distribution of DMRs of DMAPs in coordination with the position of WT UMRs. (f) Number of UMRs and DNA methylation canyons in HSCs of all genotypes analyzed. (g) Canyon regions of four genotypes at the Gata2 locus, which contains 2 type VI DMRs. The blue shaded area indicates the canyon region in WT HSCs.
Supplementary Figure 7 Enhancer methylation analysis.
(a) The DNA methylation levels of HSCs of all four genotypes in enhancer regions marked by H3K27ac in all blood progenitors and lineages. (b) The methylation levels of DMRs of six DMAPs overlapped with H3K27ac distribution in HSCs of all four genotypes. (c) Example of hypomethylated RBC progenitor enhancer DMRs in Dnmt3a−/− and DKO HSCs.
Supplementary Figure 8 Differential 5hmC alteration is associated with both gene activation and repression in HSCs.
(a) Overlapping distribution of type IV DMR and cluster 4 DhMRs at the canyon edges of the Gata2 gene. Orange shading indicates the canyon edges; gray shading shows the overlapping region for type IV DMRs and cluster 4 DhMRs. (b) Genes with type III DMRs and cluster 3 DhMRs are significantly overlapped. The P value was calculated by Fisher’s exact test. (c) 5hmC signal distribution in HSC- and RBC-specific fingerprint genes in all four genotypes. (d) Loss of TSS 5hmC signal in the Cebpe locus in DKO and Tet2−/− HSCs. The blue shaded area indicates the TSS region.
Supplementary Figure 9 Differential 5hmC analysis and the relationship between altered 5hmC and gene expression.
(a) Gene expression of all lineage-specific fingerprint genes in all four genotypes. Mean FPKM values are plotted. (b) 5hmC signal distribution in lineage-specific fingerprint genes in all four genotypes with no clear correlation with gene expression. (c) Dynamic 5hmC enrichment alteration in the promoter of the Ikzf1 locus. The blue shaded area shows the overlap of a type III DMR and a cluster 3 DhMR in the promoter region of Ikzf1.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–9. (PDF 2198 kb)
Supplementary Table 1
Differentially expressed genes of four genotypes among m12_HSC(WT), Dnmt3a_HSC,Tet2KO_HSC and DKO_HSC. (XLS 3931 kb)
Supplementary Table 2
DMRs (differentially methylated regions) in all three genotypes versus WT. (XLS 4264 kb)
Supplementary Table 3
DhMRs (differentially hydroxylmethylated regions) in all three genotypes versus WT. (XLS 7728 kb)
Rights and permissions
About this article
Cite this article
Zhang, X., Su, J., Jeong, M. et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet 48, 1014–1023 (2016). https://doi.org/10.1038/ng.3610
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.3610
This article is cited by
-
DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells
BMC Cancer (2023)
-
TET2 guards against unchecked BATF3-induced CAR T cell expansion
Nature (2023)
-
Identification of a genomic DNA sequence that quantitatively modulates KLF1 transcription factor expression in differentiating human hematopoietic cells
Scientific Reports (2023)
-
Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma
Clinical and Experimental Medicine (2023)
-
MIR retrotransposons link the epigenome and the transcriptome of coding genes in acute myeloid leukemia
Nature Communications (2022)